Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 3/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20112865 | 0.81 | NOS1 (0.46) | METAP2LRRK2ADORA2ANOS1FGFR1 | |
| SCHEMBL19204828 | 0.81 | LRRK2 (0.40) | METAP2LRRK2ADORA2ANOS1MET | |
| SCHEMBL3515094 | 0.81 | MAPT (0.46) | METAP2LRRK2ADORA2ANOS1FGFR1 | |
| SCHEMBL766959 | 0.81 | NOS1 (0.46) | METAP2LRRK2ADORA2ANOS1FGFR1 | |
| SCHEMBL18107535 | 0.81 | FGFR1 (0.44) | METAP2LRRK2ADORA2ANOS1FGFR1 | |
| SCHEMBL19204860 | 0.81 | NOS1 (0.46) | METAP2LRRK2ADORA2ANOS1FGFR1 | |
| SCHEMBL13961530 | 0.80 | METAP2 (0.38) | METAP2NOS1METFGFR1FGFR2 | |
| SCHEMBL2425031 | 0.78 | NOS1 (0.52) | METAP2NOS1METFGFR1FGFR2 | |
| SCHEMBL27229480 | 0.78 | TRPA1 (0.49) | METAP2LRRK2NOS1METFGFR1 | |
| SCHEMBL20085784 | 0.77 | SLC2A1 (0.37) | METAP2LRRK2ADORA2ANOS1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025052129-A1 | PYRIDINE DERIVATIVES WHICH ACT AS INHIBITORS OF MPTP. | NRG THERAPEUTICS LTD (GB) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| CN-116600801-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-08-15 | — | — | CN | disclosed |
| US-9604963-B2 | Amino-quinolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| US-4096333-A | NITROSATION OF A 2-METHYLACETANILIDE | TENNECO CHEMICALS, INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-3988347-A | NITROSATION OF A 2-METHYL-ACETANILIDE WITH SODIUM NITRITE | TENNECO CHEMICALS, INC. (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | METAP2 1741/4885LRRK2 1294/4885ADORA2A 321/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | METAP2 1741/4885LRRK2 1294/4885ADORA2A 321/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | METAP2 1741/4885LRRK2 1294/4885ADORA2A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.